{"product_id":"eris-swot-analysis","title":"Eris Lifesciences SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eEris Lifesciences, a prominent player in the Indian pharmaceutical market, demonstrates robust strengths in its specialized product portfolio and strong brand equity, particularly in the chronic therapy areas. However, it faces potential threats from increasing competition and evolving regulatory landscapes.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind Eris Lifesciences’ strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Focus on Chronic and Lifestyle-Related Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEris Lifesciences' core strength lies in its dedicated focus on chronic and lifestyle-related therapies, a strategic alignment with India's increasing burden of such conditions. This specialization enables them to hone their marketing efforts and product development for a substantial and growing patient demographic.\u003c\/p\u003e\n\u003cp\u003eTheir robust performance in key chronic segments, including cardiac, anti-diabetic, and neurology\/central nervous system (CNS) therapies, underscores this advantageous positioning. For instance, in the fiscal year 2023-24, Eris Lifesciences reported significant growth in its chronic business, contributing over 70% of its total revenue, with cardiac and anti-diabetic segments showing particular resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Performance and Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEris Lifesciences has showcased impressive financial momentum. For the fourth quarter of fiscal year 2024-2025, the company reported a notable surge in revenue, continuing this trend for the entirety of FY2025. This robust top-line growth was complemented by a substantial increase in net profit during the same Q4 period.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisitions and Portfolio Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEris Lifesciences has demonstrated a strong growth strategy through targeted acquisitions. A notable example is its February 2024 acquisition of a 51% stake in Swiss Parenterals, a move that bolstered its presence in the injectables market.\u003c\/p\u003e\n\u003cp\u003eFurther strengthening its portfolio, Eris acquired the India branded formulation business of Biocon Biologics in March 2024. This strategic move allowed Eris to expand into crucial therapeutic areas, including oncology and critical care.\u003c\/p\u003e\n\u003cp\u003eThese acquisitions have significantly broadened Eris Lifesciences' market reach and product offerings. The company has solidified its position as a leader, particularly in the rapidly growing insulin segment, by integrating these new capabilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Presence in the Indian Pharmaceutical Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEris Lifesciences holds a significant position as a leading player in India's domestic branded formulations market.  Its recognition as one of the youngest companies to achieve a top 20 ranking within the Indian Pharmaceutical Market (IPM) underscores its rapid growth and market penetration.\u003c\/p\u003e\n\u003cp\u003eThis established presence translates into tangible benefits, including robust distribution networks and strong brand recall among healthcare professionals and patients. For instance, as of Q4 FY24, Eris Lifesciences reported a revenue of INR 1,444 crore for the fiscal year, demonstrating its substantial operational scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Leadership:\u003c\/strong\u003e A prominent position in the branded formulations segment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eYouthful Growth:\u003c\/strong\u003e Among the youngest top 20 players in the IPM, indicating agility and rapid expansion.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBrand Equity:\u003c\/strong\u003e Strong brand recognition built through consistent performance and market engagement.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDistribution Strength:\u003c\/strong\u003e Well-established networks facilitating product reach across India.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Initiatives and Manufacturing Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEris Lifesciences distinguishes itself through robust patient-centric initiatives (PCI), offering a comprehensive platform of healthcare solutions designed to enhance patient outcomes and adherence. This focus directly addresses the evolving needs of the healthcare landscape, fostering stronger patient relationships and potentially leading to improved long-term market share.\u003c\/p\u003e\n\u003cp\u003eThe company's strategic manufacturing facility located in Guwahati, Assam, is a significant strength, providing a stable and controlled production base. This facility underpins the consistent quality and reliable supply of its diverse product portfolio, a critical factor in the competitive pharmaceutical market. For instance, in the fiscal year 2023, Eris Lifesciences reported a revenue of INR 1,270 crore, showcasing the scale of its operations and the demand for its products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient-Centric Initiatives:\u003c\/strong\u003e Eris Lifesciences' PCI platform provides integrated healthcare solutions, aiming to improve patient well-being and treatment effectiveness.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eManufacturing Prowess:\u003c\/strong\u003e The Guwahati manufacturing plant ensures supply chain resilience and stringent quality control for Eris's wide array of pharmaceutical products.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOperational Scale:\u003c\/strong\u003e With revenues reaching INR 1,270 crore in FY23, the company demonstrates significant operational capacity and market penetration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndian Pharma's Ascent: Chronic Care Focus \u0026amp; Strategic Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEris Lifesciences' strategic focus on chronic and lifestyle-related therapies, particularly in cardiac, anti-diabetic, and CNS segments, positions it well within India's growing healthcare needs. Its rapid ascent to become one of the youngest top 20 players in the Indian Pharmaceutical Market (IPM) highlights its agility and market penetration.\u003c\/p\u003e\n\u003cp\u003eThe company's robust financial performance, evidenced by significant revenue and profit growth in FY2025, underscores its operational strength. Furthermore, strategic acquisitions, such as the stakes in Swiss Parenterals and the Biocon Biologics formulation business in early 2024, have substantially expanded its product portfolio and market reach, especially in injectables, oncology, and critical care.\u003c\/p\u003e\n\u003cp\u003eEris Lifesciences boasts strong brand equity and well-established distribution networks, facilitating deep market penetration. Its patient-centric initiatives (PCI) further enhance patient engagement and treatment adherence, creating a competitive advantage. The company's manufacturing facility in Guwahati also ensures supply chain stability and product quality.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Financial \u0026amp; Market Data (FY2024-2025)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue (FY2024-2025)\u003c\/td\u003e\n\u003ctd\u003eINR 1,444 crore (Q4 FY24 figure for context, full FY25 data expected)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic Business Contribution\u003c\/td\u003e\n\u003ctd\u003eOver 70% of total revenue\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition: Swiss Parenterals\u003c\/td\u003e\n\u003ctd\u003eFebruary 2024 (51% stake)\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition: Biocon Biologics Business\u003c\/td\u003e\n\u003ctd\u003eMarch 2024\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Eris Lifesciences’s internal and external business factors, highlighting its strengths in chronic disease management and opportunities in the growing Indian pharmaceutical market, while also addressing potential weaknesses in product diversification and threats from intense competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a clear, actionable SWOT analysis for Eris Lifesciences, simplifying complex market dynamics to pinpoint pain points and strategic opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncreased Debt and Interest Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEris Lifesciences' financial position shows a notable increase in current liabilities and long-term debt as of FY2024.  This rise in borrowing directly translates to higher interest expenses, as evidenced by the substantial increase in interest costs observed in Q1 FY2025.\u003c\/p\u003e\n\u003cp\u003eThe growing debt burden poses a potential risk of liquidity strain for the company. Furthermore, increased financial leverage can negatively impact overall profitability and long-term financial stability, making the company more vulnerable to economic downturns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFluctuating Profit Margins and Net Profit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEris Lifesciences has experienced fluctuating profit margins, with a notable dip in net income and profit margin in FY2025 compared to FY2024. This variability, particularly a decrease in the net profit margin from 15.2% in FY2024 to 13.8% in FY2025, raises concerns about the company's ability to consistently translate revenue growth into stable profitability.\u003c\/p\u003e\n\u003cp\u003eSuch inconsistencies can stem from challenges in managing operational costs or implementing effective pricing strategies. This might impact investor sentiment, as a predictable and steady profit stream is often a key indicator of a company's financial health and future potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSlowing Debtor Turnover Ratio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEris Lifesciences has experienced a slowdown in its debtor turnover, with the ratio hitting a five-half-yearly period low as of June 2024. This suggests that the company is taking longer to collect payments from its customers.\u003c\/p\u003e\n\u003cp\u003eThis declining debtors turnover ratio, falling to its lowest point in the last five half-yearly periods by June 2024, points to potential inefficiencies in managing its accounts receivable. Such a trend can strain working capital and negatively affect the company's overall cash flow generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Domestic Branded Formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEris Lifesciences' significant reliance on its domestic branded formulations business, which constituted around 90% of its revenue in recent periods, presents a notable weakness. This concentration, while beneficial in a stable market, exposes the company to potential risks stemming from shifts in domestic market dynamics or unforeseen regulatory alterations impacting the branded generics sector.\u003c\/p\u003e\n\u003cp\u003eThe company's revenue streams are heavily anchored in this segment, making it vulnerable to any adverse developments. For instance, a slowdown in the Indian pharmaceutical market or stricter pricing controls on branded generics could disproportionately affect Eris's overall financial performance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevenue Concentration:\u003c\/strong\u003e Approximately 90% of Eris Lifesciences' revenue is derived from its domestic branded formulations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Sensitivity:\u003c\/strong\u003e High dependence on the Indian branded generics market makes the company susceptible to sector-specific downturns.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Risk:\u003c\/strong\u003e Potential changes in Indian pharmaceutical regulations could negatively impact the profitability of its core business.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperformance in Specific Market Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEris Lifesciences has faced challenges with underperformance in certain market segments. For instance, in May 2023, the company saw a sales decline, falling below the market average during that specific period. This indicates that while their core chronic therapy business is robust, other areas of their product portfolio may not be keeping pace with market growth.\u003c\/p\u003e\n\u003cp\u003eThis underperformance suggests potential weaknesses in Eris Lifesciences' strategy for specific therapeutic areas or product lines. While the company has demonstrated market-beating growth in some of its key chronic therapies, these isolated instances of lagging performance highlight a need for closer examination of their market penetration and competitive positioning in less successful segments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMay 2023 Sales Dip:\u003c\/strong\u003e Eris Lifesciences' sales declined in May 2023, underperforming the market average for that month.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSegment-Specific Struggles:\u003c\/strong\u003e The company's growth in certain market segments has been weaker compared to its overall performance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Pressure:\u003c\/strong\u003e This underperformance points to potential competitive challenges in specific therapeutic areas or product categories.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Headwinds: Debt, Margins, and Concentration Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEris Lifesciences' substantial debt, with current liabilities and long-term debt increasing in FY2024, leads to higher interest expenses, as seen in Q1 FY2025. This leverage heightens liquidity risks and can hinder long-term financial stability.\u003c\/p\u003e\n\u003cp\u003eThe company's profit margins have shown volatility, with a decline in net profit margin from 15.2% in FY2024 to 13.8% in FY2025, indicating potential issues with cost management or pricing strategies that could affect investor confidence.\u003c\/p\u003e\n\u003cp\u003eA weakening debtor turnover ratio, reaching a five-half-yearly low by June 2024, suggests slower collection of payments, which can strain working capital and cash flow.\u003c\/p\u003e\n\u003cp\u003eEris Lifesciences' heavy reliance on its domestic branded formulations, accounting for about 90% of revenue, makes it vulnerable to market shifts and regulatory changes within the Indian pharmaceutical sector.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2024\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003cth\u003eTrend\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Profit Margin\u003c\/td\u003e\n\u003ctd\u003e15.2%\u003c\/td\u003e\n\u003ctd\u003e13.8%\u003c\/td\u003e\n\u003ctd\u003eDecreasing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebtor Turnover Ratio (Half-Yearly)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e5-period Low (June 2024)\u003c\/td\u003e\n\u003ctd\u003eDecreasing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomestic Branded Formulations Revenue %\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003ctd\u003eStable (High Concentration)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eEris Lifesciences SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version, providing a comprehensive look at Eris Lifesciences' Strengths, Weaknesses, Opportunities, and Threats.\u003c\/p\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. It details Eris Lifesciences' internal capabilities and external market factors, offering actionable insights.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing a live preview of the actual SWOT analysis file. The complete version becomes available after checkout, allowing you to fully leverage the strategic information presented for Eris Lifesciences.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610609664377,"sku":"eris-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/eris-swot-analysis.png?v=1754741236","url":"https:\/\/growthsharematrix.com\/products\/eris-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}